Sagimet Biosciences (SGMT)
Develops selective FASN inhibitors for metabolic, dermatology, and oncology indications.
Something off on this page? Send us feedback.
Develops selective fatty-acid synthase inhibitors for metabolic, dermatology, and oncology indications, centered on denifanstat and next-generation TVB-3567. With no approved products or product-sales revenue, the business depends on clinical development and regulatory progress.
Built around proprietary selective fatty-acid synthase (FASN) inhibitors, the clinical-stage biopharmaceutical company develops programs for metabolic, dermatology, and oncology indications. Denifanstat is its current operational focus, with a U.S. program planned for moderate-to-severe acne, while TVB-3567 is a next-generation inhibitor in development.
Rather than commercial drug sales, revenue historically came from a Greater China license agreement with Ascletis. The company retains its FASN platform while licensing development, manufacturing, and commercialization rights in that territory to the partner.
Clinical development and regulatory progress determine the path forward: there are no approved products or product-sales revenue.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Target |
|---|---|---|---|
| Jan 27, 2026 | Barclays | Target | $8 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $240.1M · Total debt $1.9M · Total assets $263.4M · Shareholders' equity $256.2M
- Revenue
- $0
- Operating income
- −$15.8M
- Net income
- −$14.0M
No dividends on record.
| Institutions93 holders · as of Mar 31, 2026 | 42.97% | 26.71M shares | |
| Insiders5 holders · as of Aug 17, 2026 | 1.99% | 1.24M shares | |
| Otherremainder | 55.04% | 34.22M shares |
62.16M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (62.16M in the company's Sep 3, 2026 report, 32.58M elsewhere); stakes use the report.
This company has 2 share classes; every stake here is a share of the whole company.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Balyasny Asset Management L.P.Institution | 5.83% | 3.63M | 13Gfiled Aug 14, 2026 ↗ |
Vanguard Capital Management LLCInstitution | 3.54% | 1.10M A · 1.10M A | 13Fas of Mar 31, 2026 |
Woodline Partners LPInstitution | 3.22% | 1.00M A · 1.00M A | 13Fas of Mar 31, 2026 |
Marshall Wace, LLPInstitution | 3.11% | 966,253 A · 966,253 A | 13Fas of Mar 31, 2026 |
Baker Bros. Advisors LPInstitution | 3.07% | 952,996 A · 952,996 A | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 14, 2026 | George Kemble | director | −350,987 | $10.23 |
| Aug 11, 2026 | George Kemble | director | −20,206 | $9.95 |
| Jul 20, 2026 | George Kemble | director | −18,844 | $7.46 |
| Jul 20, 2026 | Elizabeth Rozek | officer: Chief Legal & Admin. Officer | −10,545 | $7.76 |
| Jul 20, 2026 | David Happel | director, officer: President & CEO | −64,051 | $7.76 |
- Madrigal Pharmaceuticals
Approved MASH therapy and resmetirom combination counterpart
- Novo Nordisk (ADR)
FDA-approved GLP-1 therapy for non-cirrhotic MASH
- Viking Therapeutics
Oral THR-beta agonist with completed Phase 2b MASH study
- GSK (ADR)
Phase 3 FGF21 therapy for MASH fibrosis
- Inventiva (ADR)
Pivotal Phase 3 oral pan-PPAR therapy for MASH
- Altimmune
GLP-1/glucagon dual agonist moving into Phase 3 MASH
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Sagimet Biosciences | $11.15 | +1.40% | $358.1M | — | — | — | — |
| Madrigal Pharmaceuticals | $546.41 | +1.43% | $12.64B | — | — | 9.8 | +71.2% |
| Novo Nordisk (ADR) | $47.45 | +1.49% | $207.69B | 11.5 | 18.9 | 4.1 | +0.0% |
| Viking Therapeutics | $32.98 | −1.55% | $3.91B | — | — | — | — |
| GSK (ADR) | $50.57 | +0.29% | $101.06B | 15.8 | 9.1 | 2.2 | +2.7% |
| Inventiva (ADR) | $5.00 | +3.10% | $252.6M | — | — | 215.2 | — |
| Altimmune | $3.29 | +0.46% | $637.9M | — | — | 20,576.6 | +820.0% |
| Median | 13.6 | 14.0 | 9.8 | +36.9% |